Reminyl (Galantamine)
Acetylcholinesterase inhibitor for Alzheimer's disease
Quick facts about Reminyl (Galantamine)
Key takeaways about Reminyl
- Treats Alzheimer's symptoms: Reminyl helps manage memory loss, confusion and behavioral changes in mild to moderately severe Alzheimer's disease
- Dual mechanism of action: Galantamine both inhibits acetylcholinesterase and modulates nicotinic receptors, a unique dual approach among dementia drugs
- Gradual dose titration required: Treatment starts at 8 mg daily and is slowly increased every 4 weeks to minimize side effects, up to a maximum of 24 mg daily
- Nausea is the most common side effect: Gastrointestinal symptoms typically occur during the first weeks and usually resolve as the body adjusts
- Not suitable for severe liver or kidney disease: Patients with significant hepatic or renal impairment must not take galantamine
What Is Reminyl and What Is It Used For?
Reminyl contains the active substance galantamine, an anti-dementia medication used in adults to treat the symptoms of mild to moderately severe Alzheimer's disease. It works by increasing levels of acetylcholine in the brain, a neurotransmitter critical for memory and cognitive function.
Alzheimer's disease is the most common form of dementia, accounting for approximately 60–70% of all dementia cases worldwide according to the World Health Organization. The disease causes progressive memory deterioration, confusion and behavioral changes that make it increasingly difficult to carry out normal everyday activities. These effects are believed to be caused by a deficiency of acetylcholine, a chemical messenger responsible for transmitting signals between brain cells.
Galantamine belongs to a class of medications called acetylcholinesterase inhibitors. It works by blocking the enzyme acetylcholinesterase, which normally breaks down acetylcholine in the brain. By inhibiting this enzyme, galantamine increases the amount of acetylcholine available in the synaptic cleft – the gap between nerve cells where chemical signals are transmitted. This enhanced cholinergic neurotransmission helps to partially compensate for the loss of acetylcholine-producing neurons that occurs in Alzheimer's disease.
What makes galantamine unique among acetylcholinesterase inhibitors is its dual mechanism of action. In addition to enzyme inhibition, galantamine also acts as an allosteric modulator of nicotinic acetylcholine receptors. This means it enhances the natural response of these receptors to acetylcholine, further boosting cholinergic signaling in the brain. This dual action may provide additional cognitive benefits compared to other drugs that only inhibit the enzyme.
Reminyl extended-release capsules are designed to release the medication gradually over time, allowing for once-daily dosing. This slow-release formulation helps maintain steady drug levels in the body throughout the day, which can improve tolerability and make the medication easier to take. Galantamine is also available from multiple manufacturers under various brand names including Galantamin STADA, Galantamin Sandoz, Galantamin Actavis, and Galantamin Krka.
Galantamine does not cure Alzheimer's disease and does not stop the underlying neurodegeneration. It is a symptomatic treatment that can help manage cognitive and behavioral symptoms. The benefits may be modest and tend to be most apparent in the early to moderate stages of the disease. Regular medical follow-up is essential to assess whether the medication continues to provide benefit.
What Should You Know Before Taking Reminyl?
Before starting Reminyl, your doctor needs to assess whether it is appropriate for you. There are important contraindications, precautions and potential interactions that must be considered. This section covers who should not take galantamine, special warnings, and considerations for pregnancy and breastfeeding.
Contraindications
You must not take Reminyl if any of the following apply to you:
- Allergy to galantamine: If you are allergic to galantamine hydrobromide or any other ingredient in the medication (including excipients such as gelatin, sucrose, or titanium dioxide)
- Severe liver disease: Patients with severe hepatic impairment (Child-Pugh score 10–15) must not use this medication as drug clearance is significantly reduced
- Severe kidney disease: Patients with severe renal impairment (creatinine clearance below 9 mL/min) must not use galantamine
- Combined severe liver and kidney disease: Even moderate impairment in both organs simultaneously may contraindicate use
Reminyl is approved only for Alzheimer's disease and is not recommended for other types of memory impairment or cognitive decline, including vascular dementia, Lewy body dementia, or age-related cognitive decline that does not meet diagnostic criteria for Alzheimer's disease.
Warnings and Precautions
Before starting Reminyl, your doctor should be informed if you have, or have ever had, any of the following conditions:
Reminyl can cause serious skin reactions (including Stevens-Johnson syndrome), cardiac conduction problems (bradycardia, AV block), and seizures. Seek immediate medical attention if you experience severe skin rash with blistering, heart palpitations, fainting, or convulsions. See the side effects section for complete details.
- Heart problems: Angina, previous heart attack, heart failure, slow or irregular heartbeat, prolonged QTc interval, or electrolyte imbalances (especially low potassium). Galantamine can cause bradycardia and may worsen pre-existing cardiac conduction disturbances
- Gastrointestinal conditions: Active peptic ulcer disease or history of stomach ulcers, blockage in the stomach or intestines. Cholinesterase inhibitors increase gastric acid secretion and may increase the risk of gastrointestinal bleeding
- Neurological disorders: Epilepsy or seizure history, extrapyramidal movement disorders (such as Parkinson's disease). Cholinergic drugs may lower the seizure threshold
- Respiratory conditions: Asthma, chronic obstructive pulmonary disease (COPD), or active respiratory infections. Cholinergic stimulation can increase bronchial secretions and airway resistance
- Urinary tract problems: Urinary retention or obstruction. Cholinergic drugs may worsen urinary symptoms
- Recent surgery: If you have recently undergone surgery of the stomach, intestines, or urinary bladder, your doctor may decide Reminyl is not suitable
Your doctor should regularly monitor your weight during treatment, as galantamine can cause clinically significant weight loss. This is particularly important in elderly patients who may already be at risk of malnutrition. If significant weight loss occurs, the doctor may need to reassess whether to continue treatment.
Children and Adolescents
Reminyl is not recommended for use in children and adolescents under 18 years of age. There is no relevant indication for galantamine in the pediatric population, and its safety and efficacy have not been established in this age group.
Pregnancy and Breastfeeding
If you are pregnant, think you may be pregnant, or are planning to have a baby, consult your doctor before using Reminyl. There are limited data on the use of galantamine in pregnant women. Animal studies have shown some reproductive toxicity at high doses, and the potential risk to the human fetus is unknown. The medication should only be used during pregnancy if the potential benefit justifies the potential risk.
You should not breastfeed while taking Reminyl. It is not known whether galantamine passes into human breast milk, but given the potential for adverse effects in nursing infants, breastfeeding is not recommended during treatment.
Driving and Operating Machinery
Reminyl may cause dizziness, drowsiness, and excessive sleepiness, particularly during the first weeks of treatment. If these symptoms affect you, do not drive, operate machinery, or perform activities that require alertness. Alzheimer's disease itself can also impair the ability to drive safely, and patients should be regularly assessed for their fitness to drive regardless of medication.
How Does Reminyl Interact with Other Drugs?
Galantamine has clinically significant interactions with several drug classes. It must not be combined with other cholinesterase inhibitors, and certain medications can increase its side effects or alter its blood levels. Always inform your doctor about all medications, supplements and herbal products you are taking.
Drug interactions with galantamine fall into several categories: drugs that should never be combined with it, drugs that may increase side effects, and drugs that affect how galantamine is metabolized in the body. Understanding these interactions is critical for safe treatment.
Major Interactions – Do Not Combine
Reminyl must not be used together with other medications that work in a similar way. These include:
- Other cholinesterase inhibitors: Donepezil or rivastigmine (used for Alzheimer's disease). Combining these drugs increases the risk of excessive cholinergic stimulation
- Cholinergic agonists: Ambenonium, neostigmine, or pyridostigmine (used for myasthenia gravis). The combined cholinergic effect can cause dangerous overstimulation
- Oral pilocarpine: Used for dry mouth or dry eyes. May enhance cholinergic side effects when combined with galantamine
Interactions That May Increase Side Effects
| Drug | Category | Effect | Action |
|---|---|---|---|
| Paroxetine, Fluoxetine | Antidepressants (SSRIs) | Inhibit CYP2D6, increasing galantamine levels | Dose reduction may be needed |
| Quinidine | Antiarrhythmic | Strong CYP2D6 inhibitor, significantly increases galantamine exposure | Dose reduction recommended |
| Ketoconazole | Antifungal | Inhibits CYP3A4, increases galantamine levels | Dose reduction may be needed |
| Erythromycin | Antibiotic (macrolide) | Moderate CYP3A4 inhibitor, increases galantamine exposure | Monitor for increased side effects |
| Ritonavir | Antiretroviral (HIV) | Potent CYP3A4 inhibitor, substantially increases galantamine levels | Dose reduction recommended |
| NSAIDs (e.g., ibuprofen) | Pain relievers | Increased risk of gastrointestinal ulceration and bleeding | Use with caution; consider gastroprotection |
| Digoxin | Cardiac glycoside | Both drugs slow heart rate; risk of severe bradycardia | ECG monitoring recommended |
| Beta-blockers, calcium channel blockers | Antihypertensives | Additive bradycardic effect; risk of heart block | Heart rate monitoring; ECG if indicated |
| Amiodarone | Antiarrhythmic | Both prolong QTc interval; risk of cardiac arrhythmia | ECG monitoring; avoid if possible |
| QTc-prolonging drugs | Various | Additive QTc prolongation; increased arrhythmia risk | ECG monitoring required |
If you are taking any of the CYP2D6 or CYP3A4 inhibitors listed above, your doctor may prescribe a lower dose of galantamine. This is because these medications slow down the body's ability to metabolize galantamine, resulting in higher blood levels and an increased risk of side effects.
Galantamine may enhance the effects of certain anaesthetic agents, particularly succinylcholine-type muscle relaxants. If you are scheduled for surgery requiring general anaesthesia, inform your anaesthetist well in advance that you are taking Reminyl.
What Is the Correct Dosage of Reminyl?
Reminyl extended-release capsules are taken once daily in the morning with food. Treatment starts at 8 mg daily and is gradually increased every 4 weeks or more. The maximum recommended dose is 24 mg once daily. Always follow your doctor's specific instructions for your situation.
The dosage of galantamine follows a carefully structured titration schedule designed to minimize gastrointestinal side effects while achieving optimal therapeutic benefit. Your doctor will determine the appropriate dose based on your response, tolerability, and any liver or kidney function concerns.
Adults – Standard Dosing
| Phase | Daily Dose | Duration | Notes |
|---|---|---|---|
| Starting dose | 8 mg once daily | At least 4 weeks | Take in the morning with food |
| First increase | 16 mg once daily | At least 4 weeks | Only increase if 8 mg is well tolerated |
| Second increase | 24 mg once daily | Maintenance | Maximum recommended dose |
Your doctor will schedule regular follow-up appointments to monitor how the medication is working and to discuss your overall wellbeing. If you feel that Reminyl is too strong or too weak in effect, speak to your doctor or pharmacist before making any dose changes.
Special Populations
Patients with Liver Impairment
For patients with moderate hepatic impairment (Child-Pugh score 7–9), the doctor may prescribe a lower dose, typically starting at 8 mg every other day for one week, then 8 mg daily for at least 4 weeks before any increase. The maximum dose should not exceed 16 mg daily. Patients with severe hepatic impairment must not take galantamine.
Patients with Kidney Impairment
For patients with moderate renal impairment, dose adjustments may be necessary. The maximum dose should generally not exceed 16 mg daily. Patients with severe renal impairment (creatinine clearance below 9 mL/min) must not take galantamine.
Elderly Patients
No specific dose adjustment is required based on age alone. However, elderly patients are more likely to have reduced liver or kidney function, which may require dose modifications. Careful monitoring of weight, nutrition and hydration status is important in this population.
How to Take Reminyl
Reminyl extended-release capsules must be swallowed whole and must never be chewed or crushed. The extended-release mechanism relies on the intact capsule structure to deliver the medication gradually over the day. Breaking or chewing the capsule would release the entire dose at once, potentially causing more severe side effects.
- Take the capsule once daily in the morning with food
- Swallow with a full glass of water or another beverage
- Drink plenty of fluids throughout the day to prevent dehydration
- Try to take the medication at the same time each day
Switching from Immediate-Release Tablets to Extended-Release Capsules
If you are currently taking Reminyl as immediate-release tablets or oral solution (taken twice daily) and your doctor switches you to extended-release capsules:
- Take your last dose of tablets or oral solution in the evening
- Take your first extended-release capsule the next morning
- Do not take more than one extended-release capsule per day
- While using extended-release capsules, do not take immediate-release tablets or oral solution simultaneously
Missed Dose
If you forget to take a dose of Reminyl, skip the missed dose entirely and take your next dose at the usual time. Do not take a double dose to compensate for a forgotten dose. If you miss more than one dose in a row, contact your doctor for guidance, as the dose may need to be re-titrated from a lower level to reduce the risk of side effects.
Overdose
If you have taken too much Reminyl, contact emergency services or go to your nearest emergency department immediately. Bring any remaining capsules and the packaging with you. Signs of overdose may include:
- Severe nausea and vomiting
- Muscle weakness
- Dangerously slow heart rate (bradycardia)
- Seizures (convulsions)
- Loss of consciousness
The management of galantamine overdose is primarily supportive. Atropine may be administered intravenously as an antidote for severe cholinergic effects such as life-threatening bradycardia. In cases of recent ingestion, gastric lavage or activated charcoal may be considered if appropriate.
What Are the Side Effects of Reminyl?
Like all medicines, Reminyl can cause side effects, although not everyone experiences them. The most common side effects are nausea and vomiting, which usually occur during the initial weeks of treatment and typically improve as the body adjusts. Some side effects are serious and require immediate medical attention.
- Severe skin reactions: Blistering or peeling skin, particularly around the mouth, nose, eyes and genitals (Stevens-Johnson syndrome); red rash covered with small pus-filled blisters (acute generalized exanthematous pustulosis); or rash with target-like spots
- Heart problems: Changes in heart rhythm including very slow heartbeat, extra beats, or rapid/irregular heartbeat (palpitations)
- Seizures: Convulsions or fits
The following side effects have been observed with galantamine, organized by frequency. Understanding these frequencies helps put the risk into perspective:
Very Common Side Effects
- Nausea
- Vomiting
These are most likely during the first weeks or when the dose is increased. They usually diminish gradually as the body adapts and typically last only a few days. Your doctor may recommend drinking more fluids and can prescribe anti-nausea medication if needed.
Common Side Effects
- Decreased appetite and weight loss
- Hallucinations (seeing, feeling or hearing things that are not there)
- Depression
- Dizziness or fainting
- Muscle tremor or muscle spasms
- Headache
- Extreme tiredness, weakness or general malaise
- Excessive drowsiness with low energy
- High blood pressure
- Abdominal pain or discomfort
- Diarrhea
- Digestive problems (dyspepsia)
- Falls
- Injuries
Uncommon Side Effects
- Allergic reactions
- Dehydration (insufficient body water)
- Tingling or numbness in the skin (paraesthesia)
- Taste disturbances (dysgeusia)
- Daytime sleepiness (somnolence)
- Difficulty controlling body movements (extrapyramidal disorder)
- Blurred vision
- Ringing in the ears (tinnitus)
- Low blood pressure (hypotension)
- Flushing
- Retching
- Excessive sweating (hyperhidrosis)
- Muscle weakness
- Elevated liver enzyme levels in blood tests
Rare Side Effects
- Inflammation of the liver (hepatitis)
- Stevens-Johnson syndrome (severe skin reaction with blistering)
- Acute generalized exanthematous pustulosis (red rash with pus-filled blisters)
- Erythema multiforme (rash with target-like spots)
If you experience any side effects, even those not listed here, talk to your doctor or pharmacist. Reporting side effects helps regulatory agencies continue to monitor the benefit-risk balance of medications. In the UK, side effects can be reported via the Yellow Card Scheme; in the US, through the FDA MedWatch program; and in the EU, through national pharmacovigilance systems.
Cardiac Monitoring
Because galantamine can affect heart rhythm, your doctor may order an electrocardiogram (ECG) before starting treatment and periodically during therapy, particularly if you are also taking medications that affect heart rhythm (antiarrhythmics, beta-blockers, digoxin). Heart rhythm changes, including bradycardia and QTc prolongation, are considered common side effects (affecting up to 1 in 10 users) and may be detected on ECG before you notice any symptoms.
How Should You Store Reminyl?
Store Reminyl extended-release capsules at room temperature (below 30°C / 86°F), in the original packaging, and keep them out of the reach and sight of children. Do not use the medication after the expiry date printed on the carton and blister pack.
Proper storage is essential to ensure that your medication remains effective and safe to use throughout its shelf life. Follow these guidelines:
- Temperature: Store at or below 30°C (86°F). Do not freeze. Avoid exposing the capsules to excessive heat or direct sunlight
- Packaging: Keep the capsules in their original blister packaging until you are ready to take them. This protects them from moisture and light
- Children: Store out of the sight and reach of children. Consider using a locked medicine cabinet
- Expiry date: Check the expiry date (marked "EXP") on the carton and blister foil. The expiry date refers to the last day of the stated month. Do not use the medication after this date
- Disposal: Do not dispose of unused medication in household waste or flush it down the drain. Return unused or expired medications to your pharmacy for safe disposal. This helps protect the environment
Reminyl 8 mg capsules are white and marked "G8". The 16 mg capsules are pink and marked "G16". The 24 mg capsules are light brown and marked "G24". If your capsules look different from what you expect, contact your pharmacist before taking them.
What Does Reminyl Contain?
Reminyl extended-release capsules contain galantamine (as hydrobromide) as the active ingredient, along with several inactive excipients that help form the capsule shell and control drug release. The 8 mg, 16 mg and 24 mg capsules contain slightly different coloring agents.
The active substance in each capsule is galantamine, present as galantamine hydrobromide. Each capsule delivers 8 mg, 16 mg, or 24 mg of galantamine.
The other ingredients (excipients) include:
- Capsule contents: Diethyl phthalate, ethylcellulose, hypromellose, macrogol 400, maize starch, sucrose
- Capsule shell: Gelatin, titanium dioxide (E171), black iron oxide (E172), shellac, propylene glycol (E1520)
- 16 mg capsules additionally contain: Red iron oxide (E172)
- 24 mg capsules additionally contain: Red iron oxide (E172) and yellow iron oxide (E172)
This medication contains sucrose (a type of sugar). If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.
Reminyl is manufactured by Janssen-Cilag SpA in Latina, Italy, and is marketed by Essential Pharma Limited (Malta). The medication is available in blister packs of 7, 28, 56, or 84 capsules, or in bottles of 300 capsules. Not all pack sizes may be available in every market.
What Happens If You Stop Taking Reminyl?
Do not stop taking Reminyl without consulting your doctor first. Abrupt discontinuation may lead to a noticeable worsening of Alzheimer's symptoms. If treatment is to be stopped, your doctor will advise on the most appropriate approach.
It is important to continue taking Reminyl regularly as prescribed for the treatment of your condition. The medication works by maintaining higher levels of acetylcholine in the brain, and stopping it can lead to a decline in cognitive function as these levels drop. While galantamine does not cause physical dependence, the symptoms of Alzheimer's disease may worsen relatively quickly after discontinuation.
If you and your doctor decide to stop treatment – whether due to side effects, lack of benefit, or disease progression – your doctor will guide you through the process. In some cases, a gradual dose reduction may be recommended rather than abrupt cessation, although there are no specific withdrawal symptoms associated with galantamine.
Regular reassessment of the benefit of continued treatment is recommended. If, after an adequate trial period (typically at least 3–6 months at an effective dose), there is no evidence of clinical benefit or the disease has progressed to a severe stage, the doctor may recommend stopping the medication.
Frequently Asked Questions About Reminyl
Reminyl (galantamine) differs from other Alzheimer's medications in its mechanism of action. While donepezil and rivastigmine are also cholinesterase inhibitors, galantamine has a unique dual action: it both inhibits acetylcholinesterase and modulates nicotinic acetylcholine receptors. This dual mechanism may provide additional synaptic enhancement. Memantine, another Alzheimer's drug, works through an entirely different mechanism (NMDA receptor antagonism) and is typically used in moderate to severe disease. Your doctor will choose the most appropriate medication based on your individual circumstances.
It is generally advisable to limit or avoid alcohol while taking Reminyl. Alcohol can worsen the side effects of galantamine, particularly drowsiness, dizziness and gastrointestinal symptoms. Both alcohol and galantamine can also affect liver function. Additionally, alcohol may independently impair cognitive function, counteracting the potential benefits of the medication. Discuss your alcohol consumption with your doctor for personalized guidance.
The effects of Reminyl are not usually noticeable immediately. It typically takes 4 to 12 weeks of treatment at a therapeutic dose before cognitive benefits can be assessed. Since the dose is gradually increased over the first 8 weeks or more, the full effect may not be apparent until several months into treatment. Improvements may be subtle and are often more noticeable to caregivers than to the patient themselves. Your doctor will assess the medication's effectiveness through cognitive tests and discussions about daily functioning.
Nausea is the most common side effect of Reminyl and usually occurs during the first weeks of treatment or after a dose increase. To reduce nausea: always take the capsule with food, drink plenty of fluids throughout the day, eat smaller and more frequent meals, and avoid lying down immediately after taking the medication. If nausea persists or is severe, contact your doctor – they may prescribe an anti-nausea medication or adjust your dose. Do not stop taking Reminyl without medical advice.
Yes, galantamine is available as a generic medication from several manufacturers. Generic versions include Galantamin STADA, Galantamin Sandoz, Galantamin Actavis, Galantamin Krka, and Galantamine Medical Valley. These generics contain the same active ingredient (galantamine hydrobromide) at the same strengths as the branded Reminyl product and have been approved by regulatory authorities as bioequivalent. Your pharmacist may dispense a generic version unless your doctor specifically prescribes the branded product.
No, Reminyl cannot cure Alzheimer's disease. It is a symptomatic treatment that helps manage cognitive symptoms such as memory loss, confusion and difficulties with daily activities. The medication works by boosting acetylcholine levels in the brain, but it does not address the underlying neurodegenerative process. While it may temporarily stabilize or modestly improve symptoms, the disease typically continues to progress over time. Research into disease-modifying treatments for Alzheimer's is ongoing, with several newer approaches targeting amyloid plaques and tau tangles currently in clinical trials or recently approved.
References
This article is based on the following international medical sources and guidelines. All medical claims are supported by evidence level 1A (systematic reviews and randomized controlled trials) where available.
- European Medicines Agency (EMA). Reminyl – Summary of Product Characteristics. EMA/CHMP. Updated 2025. Available at: www.ema.europa.eu
- Birks J, Grimley Evans J. Galantamine for Alzheimer's disease. Cochrane Database of Systematic Reviews. 2015;(4):CD001747. doi:10.1002/14651858.CD001747.pub3
- World Health Organization. Dementia: Key Facts. WHO Fact Sheet. Updated 2023. Available at: www.who.int
- National Institute for Health and Care Excellence (NICE). Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease. NICE Technology Appraisal Guidance TA217. Updated 2023.
- U.S. Food and Drug Administration (FDA). Razadyne/Razadyne ER (galantamine hydrobromide) Prescribing Information. FDA Label. 2024.
- British National Formulary (BNF). Galantamine. NICE BNF. Updated 2025. Available at: bnf.nice.org.uk
- Loy C, Schneider L. Galantamine for Alzheimer's disease and mild cognitive impairment. Cochrane Database of Systematic Reviews. 2006;(1):CD001747.
- Livingston G, Huntley J, Sommerlad A, et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. The Lancet. 2020;396(10248):413-446.
Editorial Team
This article has been written and medically reviewed by the iMedic Medical Editorial Team – a multidisciplinary panel of licensed physicians and clinical pharmacologists with expertise in neurology, geriatric medicine and pharmacotherapy.
Medical Content
Written by medical professionals with clinical expertise in neurology, dementia care and psychopharmacology. Content follows WHO, EMA and NICE guidelines.
Medical Review
Independently reviewed by the iMedic Medical Review Board. Evidence graded using the GRADE framework. No pharmaceutical funding or conflicts of interest.
Published: | Last medically reviewed: | Next review due: